Stifel Cuts Price Target on TeamHealth Holdings (TMH) to $43; Reiterates Buy Following CEO Appointment

September 9, 2016 9:03 AM EDT
Get Alerts TMH Hot Sheet
Price: $43.45 --0%

Rating Summary:
    4 Buy, 14 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 4 | Down: 5 | New: 17
Trade TMH Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Stifel maintained a Buy rating on TeamHealth Holdings (NYSE: TMH), and cut the price target to $43.00 (from $48.00). The company announced that Leif Murphy is now President and Chief Executive Officer as former CEO Michael Snow steps aside. Stifel views this transition positively. TMH also affirmed their guidance of net revenue of $4.64 billion - $4.71 billion, an implied net revenue growth rate of 29% to 31% and EBITDA margins expected to be 10.5%.

Analyst Chad Vanacore commented, "We are reducing our 2016 revenue estimates from $4.74 billion to $4.65 billion and adjusted EBITDA from $508.5 million to $490.3 million reflecting revenues and margins on the low end of management guidance. We expect operations to bounce back in 2017 and estimate margin expansion back toward the higher end of the 10.5-11% range as the company digests the recent IPC acquisition."

For an analyst ratings summary and ratings history on Team Health click here. For more ratings news on Team Health click here.

Shares of Team Health closed at $35.29 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS Change, Analyst PT Change

Related Entities

Stifel, Definitive Agreement

Add Your Comment